Manufacturer of Controlled Substances; Notice of Application; Apertus Pharmaceuticals, 46372 [2013-18339]
Download as PDF
<![CDATA[
46372
Federal Register / Vol. 78, No. 147 / Wednesday, July 31, 2013 / Notices
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: July 23, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Manufacturer of Controlled
Substances; Notice of Application;
Apertus Pharmaceuticals
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Ampac Fine Chemicals, LLC.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 6, 2013,
AMPAC Fine Chemicals, LLC., Highway
50 and Hazel Avenue, Building 05001,
Rancho Cordova, California 95670,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Schedule
mstockstill on DSK4VPTVN1PROD with NOTICES
II
II
II
Tapentadol (9780) ........................
II
The company is a contract
manufacturer. In reference to Poppy
Straw Concentrate the company will
manufacture Thebaine intermediates to
sale to its customers for further
manufacture. No other activity for this
drug code is authorized for this
registration.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than September 30, 2013.
VerDate Mar<15>2010
16:14 Jul 30, 2013
Jkt 229001
BILLING CODE 4410–09–P
Drug Enforcement Administration
BILLING CODE 4410–09–P
Methylphenidate (1724) ................
Thebaine (9333) ...........................
Poppy Straw Concentrate (9670)
[FR Doc. 2013–18337 Filed 7–30–13; 8:45 am]
DEPARTMENT OF JUSTICE
[FR Doc. 2013–18331 Filed 7–30–13; 8:45 am]
Drug
Dated: July 23, 2013.
Joseph T. Rannazzisi
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on June 14, 2013,
Apertus Pharmaceuticals, 331 Consort
Drive, St. Louis, Missouri 63011, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
II
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances to make reference standards
for distribution to their customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR § 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than September 30, 2013.
Dated: July 23, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–18339 Filed 7–30–13; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Research Triangle Institute
By Notice dated April 16, 2013, and
published in the Federal Register on
April 23, 2013, 78 FR 23958, Research
Triangle Institute, Poonam G. Pande,
Ph.D., RPH, RAC, Hermann Building,
East Institute Drive, P.O. Box 12194,
Research Triangle Park, North Carolina
27709, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
Marihuana (7360) .........................
Cocaine (9041) .............................
Schedule
I
II
The Institute will manufacture
marihuana, and cocaine derivatives for
use by their customers in analytical kits,
reagents, and reference standards as
directed by the National Institute on
Drug Abuse.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Research Triangle Institute to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Research Triangle Institute
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR
§ 1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: July 23, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–18336 Filed 7–30–13; 8:45 am]
BILLING CODE 4410–09–P
Frm 00061
Fmt 4703
Sfmt 9990
E:\FR\FM\31JYN1.SGM
31JYN1
]]>Agencies
[Federal Register Volume 78, Number 147 (Wednesday, July 31, 2013)]
[Notices]
[Page 46372]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-18339]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application;
Apertus Pharmaceuticals
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on June 14, 2013, Apertus
Pharmaceuticals, 331 Consort Drive, St. Louis, Missouri 63011, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of the following basic classes of
controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Alfentanil (9737).......................... II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture small quantities of the listed
controlled substances to make reference standards for distribution to
their customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR Sec. 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than September 30, 2013.
Dated: July 23, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-18339 Filed 7-30-13; 8:45 am]
BILLING CODE 4410-09-P
